OBJECTIVE: Little is known about the long-term costs of lupus nephritis (LN). The costs were compared between patients with and without LN using multistate modeling. METHODS: Patients from 32 centers in 11 countries were enrolled in the Systemic Lupus International Collaborating Clinics inception cohort within 15 months of diagnosis and provided annual data on renal function, hospitalizations, medications, dialysis, and selected procedures. LN was diagnosed by renal biopsy or the American College of Rheumatology classification criteria. Renal function was assessed annually using the estimated glomerular filtration rate (GFR) or estimated proteinuria. A multistate model was used to predict 10-year cumulative costs by multiplying annual costs...
Objective. To compare costs and quality of life (QoL) between SLE patients with and without renal da...
Background and objectives: Despite existing therapies, people with lupus nephritis progress to kidne...
Objective We estimated the incremental (extra) direct medical costs of a population-based cohort of...
Objective: Little is known about the long-term costs of lupus nephritis (LN). The costs were compare...
OBJECTIVE: Little is known about the long-term costs of lupus nephritis (LN). These were compared be...
OBJECTIVE: Little is known about the long-term costs of lupus nephritis (LN). The costs were compare...
INTRODUCTION: Few studies have evaluated the economic burden of lupus nephritis (LN). The aim of thi...
OBJECTIVE: There is a paucity of data regarding health care costs associated with damage accrual in ...
Objective: There is a paucity of data regarding health care costs associated with damage accrual in ...
Objective. To study bidirectional change and predictors of change in estimated glomerular filtration...
OBJECTIVE: To study bidirectional change and predictors of change in estimated glomerular filtration...
Objective: To study the annual direct and indirect costs in systemic lupus erythematosus (SLE) and h...
Objectives. Systemic lupus erythematosus (SLE) is an autoimmune disorder that can affect any system ...
OBJECTIVE: Treat-to-target end points for systemic lupus erythematosus (SLE) have been assessed for ...
OBJECTIVE: To determine the annual direct, indirect and total costs and predictors of costs in patie...
Objective. To compare costs and quality of life (QoL) between SLE patients with and without renal da...
Background and objectives: Despite existing therapies, people with lupus nephritis progress to kidne...
Objective We estimated the incremental (extra) direct medical costs of a population-based cohort of...
Objective: Little is known about the long-term costs of lupus nephritis (LN). The costs were compare...
OBJECTIVE: Little is known about the long-term costs of lupus nephritis (LN). These were compared be...
OBJECTIVE: Little is known about the long-term costs of lupus nephritis (LN). The costs were compare...
INTRODUCTION: Few studies have evaluated the economic burden of lupus nephritis (LN). The aim of thi...
OBJECTIVE: There is a paucity of data regarding health care costs associated with damage accrual in ...
Objective: There is a paucity of data regarding health care costs associated with damage accrual in ...
Objective. To study bidirectional change and predictors of change in estimated glomerular filtration...
OBJECTIVE: To study bidirectional change and predictors of change in estimated glomerular filtration...
Objective: To study the annual direct and indirect costs in systemic lupus erythematosus (SLE) and h...
Objectives. Systemic lupus erythematosus (SLE) is an autoimmune disorder that can affect any system ...
OBJECTIVE: Treat-to-target end points for systemic lupus erythematosus (SLE) have been assessed for ...
OBJECTIVE: To determine the annual direct, indirect and total costs and predictors of costs in patie...
Objective. To compare costs and quality of life (QoL) between SLE patients with and without renal da...
Background and objectives: Despite existing therapies, people with lupus nephritis progress to kidne...
Objective We estimated the incremental (extra) direct medical costs of a population-based cohort of...